IL146805A0 - Novel epidermal growth factor receptor-binding compounds for positron emission tomography - Google Patents

Novel epidermal growth factor receptor-binding compounds for positron emission tomography

Info

Publication number
IL146805A0
IL146805A0 IL14680500A IL14680500A IL146805A0 IL 146805 A0 IL146805 A0 IL 146805A0 IL 14680500 A IL14680500 A IL 14680500A IL 14680500 A IL14680500 A IL 14680500A IL 146805 A0 IL146805 A0 IL 146805A0
Authority
IL
Israel
Prior art keywords
growth factor
factor receptor
epidermal growth
positron emission
emission tomography
Prior art date
Application number
IL14680500A
Other languages
English (en)
Original Assignee
Hadasit Med Res Service
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Yissum Res Dev Co filed Critical Hadasit Med Res Service
Publication of IL146805A0 publication Critical patent/IL146805A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14680500A 1999-06-01 2000-05-19 Novel epidermal growth factor receptor-binding compounds for positron emission tomography IL146805A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/322,979 US6126917A (en) 1999-06-01 1999-06-01 Epidermal growth factor receptor binding compounds for positron emission tomography
PCT/US2000/013749 WO2000072849A1 (en) 1999-06-01 2000-05-19 Novel epidermal growth factor receptor-binding compounds for positron emission tomography

Publications (1)

Publication Number Publication Date
IL146805A0 true IL146805A0 (en) 2002-07-25

Family

ID=23257276

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14680500A IL146805A0 (en) 1999-06-01 2000-05-19 Novel epidermal growth factor receptor-binding compounds for positron emission tomography

Country Status (7)

Country Link
US (1) US6126917A (https=)
EP (1) EP1180034A4 (https=)
JP (1) JP2003500450A (https=)
AU (1) AU4857400A (https=)
CA (1) CA2375826A1 (https=)
IL (1) IL146805A0 (https=)
WO (1) WO2000072849A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001272904A1 (en) * 2000-09-07 2002-03-22 Wisconsin Alumni Research Foundation Synthesis of 17f labeled fluoroalkanes
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
US20040197335A1 (en) * 2001-06-14 2004-10-07 Shimon Slavin Non-myeloablative tolerogenic treatment with tyrphostins
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
CA2514479A1 (en) * 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
UY28441A1 (es) * 2003-07-29 2005-02-28 Astrazeneca Ab Derivados de quinazolina
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
ES2279441T3 (es) * 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
WO2005030757A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
NO20035682D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av ösofagkreft og Barretts ösofag
NO20035681D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av lungekreft
KR20070107151A (ko) * 2005-02-26 2007-11-06 아스트라제네카 아베 티로신 키나제 억제제로서의 퀴나졸린 유도체
EP1957468A2 (en) * 2005-09-06 2008-08-20 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4 - (phenylamino)quinazolines useful as irreversible inhibitors of epidermal growth factor receptor tyrosine kinase
JP4945133B2 (ja) * 2006-01-19 2012-06-06 富士フイルムＲｉファーマ株式会社 ４−フェノキシキナゾリン誘導体放射性化合物
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) * 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
FR2926079B1 (fr) 2008-01-03 2012-12-28 Commissariat Energie Atomique Procede de preparation d'un derive de purine marque, ledit derive et ses utilisations
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
EP2313397B1 (de) * 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US8753605B2 (en) 2010-08-31 2014-06-17 The Board Of Trustees Of The Leland Stanford Junior University Imaging probes, methods of making imaging probes, and methods of imaging
CN103254140B (zh) * 2012-02-17 2016-02-17 北京师范大学 新型18f标记取代喹唑啉类化合物及其制备方法和肿瘤pet显像应用
WO2017122205A1 (en) 2016-01-13 2017-07-20 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57144266A (en) * 1981-03-04 1982-09-06 Sankyo Co Ltd 4-anilinoquinazoline derivative, its preparation, and analgesic and antiphlogistic agent containing said derivative as active component
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
DE69720965T2 (de) * 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
EP0954315A2 (en) * 1996-09-13 1999-11-10 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
IL139641A0 (en) * 1998-05-28 2002-02-10 Parker Hughes Inst Quinazolines for treating brain tumor
US6172071B1 (en) * 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
KR20010089171A (ko) * 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
EP1162974A1 (en) * 1999-03-19 2001-12-19 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof

Also Published As

Publication number Publication date
WO2000072849A1 (en) 2000-12-07
US6126917A (en) 2000-10-03
CA2375826A1 (en) 2000-12-07
AU4857400A (en) 2000-12-18
EP1180034A4 (en) 2003-05-14
JP2003500450A (ja) 2003-01-07
EP1180034A1 (en) 2002-02-20

Similar Documents

Publication Publication Date Title
IL146805A0 (en) Novel epidermal growth factor receptor-binding compounds for positron emission tomography
IL150694A0 (en) Data acquisition for computed tomography
AU3889500A (en) Radiographic reference marker
AU4462800A (en) Single photon emission computed tomography system
IL145199A0 (en) Permeability-modulated carrier referencing
GB9927555D0 (en) X-ray fluorescence apparatus
IL146210A0 (en) Pyrimidinone compounds
PL354360A1 (en) New compounds
EP1256817A4 (en) POSITRON EMITTING TOMOGRAPH
HUP0500037A3 (en) Process for preparing insulin compounds
PL372605A1 (en) Preparations containing at least one diformate
GB9906624D0 (en) Novel compounds
EG24063A (en) Novel compounds
AU2002225998A1 (en) Data acquisition for computed tomography
GB0103896D0 (en) Dimeric compounds
GB9907860D0 (en) Novel compounds
GB9901256D0 (en) Novel compounds
AU2001275742A1 (en) Computed tomography
GB9902070D0 (en) Novel compounds
GB9902937D0 (en) Novel compounds
AU6437100A (en) Method for preparing optionally substituted dichloroaromatic compounds
GB9912971D0 (en) Medical composition
PL109360U1 (en) Medical flask
GB9908785D0 (en) Novel compounds
GB9903536D0 (en) Novel compounds